Evaluation of KX2-391 in Patients With Advanced Malignancies
NCT00658970
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Lymphoma
Interventions
DRUG:
KX2-391
Sponsor
Athenex, Inc.